146 related articles for article (PubMed ID: 31524018)
1. Leukemic lineage switch in a t(8;22)(p11.2;q11.2)/
Manur R; Sung PJ; Loren AW; Ritchie EK; Frank D; Bagg A; Geyer JT; Bogusz AM
Leuk Lymphoma; 2020 Feb; 61(2):450-454. PubMed ID: 31524018
[No Abstract] [Full Text] [Related]
2. A rare case of atypical chronic myeloid leukemia associated with t(8;22)(p11.2;q11.2)/ BCR-FGFR1 rearrangement: A case report and literature review.
Washburn E; Bayerl MG; Ketterling RP; Malysz J
Cancer Genet; 2021 Nov; 258-259():69-73. PubMed ID: 34551378
[TBL] [Abstract][Full Text] [Related]
3. Myeloid and lymphoid neoplasm with abnormalities of FGFR1 presenting with trilineage blasts and RUNX1 rearrangement: a case report and review of literature.
Kumar KR; Chen W; Koduru PR; Luu HS
Am J Clin Pathol; 2015 May; 143(5):738-48. PubMed ID: 25873510
[TBL] [Abstract][Full Text] [Related]
4. Pemigatinib for the treatment of myeloid/lymphoid neoplasms with
Freyer CW; Hughes ME; Carulli A; Bagg A; Hexner E
Expert Rev Anticancer Ther; 2023 Apr; 23(4):351-359. PubMed ID: 36927350
[TBL] [Abstract][Full Text] [Related]
5. Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase.
Montenegro-Garreaud X; Miranda RN; Reynolds A; Tang G; Wang SA; Yabe M; Wang W; Fang L; Bueso-Ramos CE; Lin P; Medeiros LJ; Lu X
Hum Pathol; 2017 Jul; 65():147-156. PubMed ID: 28551329
[TBL] [Abstract][Full Text] [Related]
6. Myeloid/lymphoid neoplasms with FGFR1 rearrangement.
Strati P; Tang G; Duose DY; Mallampati S; Luthra R; Patel KP; Hussaini M; Mirza AS; Komrokji RS; Oh S; Mascarenhas J; Najfeld V; Subbiah V; Kantarjian H; Garcia-Manero G; Verstovsek S; Daver N
Leuk Lymphoma; 2018 Jul; 59(7):1672-1676. PubMed ID: 29119847
[TBL] [Abstract][Full Text] [Related]
7. Acute leukemia showing t(8;22)(p11;q11), myelodysplasia, CD13/CD33/CD19 expression and immunoglobulin heavy chain gene rearrangement.
Shimanuki M; Sonoki T; Hosoi H; Watanuki J; Murata S; Mushino T; Kuriyama K; Tamura S; Hatanaka K; Hanaoka N; Nakakuma H
Acta Haematol; 2013; 129(4):238-42. PubMed ID: 23328683
[TBL] [Abstract][Full Text] [Related]
8. Myeloid/lymphoid neoplasm with CEP110-FGFR1 fusion: An analysis of 16 cases show common features and poor prognosis.
Chen M; Wang K; Cai X; Zhang X; Chao H; Chen S; Shen H; Wang Q; Zhang R
Hematology; 2021 Dec; 26(1):153-159. PubMed ID: 33491601
[No Abstract] [Full Text] [Related]
9. Myeloid and lymphoid neoplasm with FGFR1 abnormality.
Keane C; Henden A; Mills T; Wood P
Br J Haematol; 2009 May; 145(4):440. PubMed ID: 19076174
[No Abstract] [Full Text] [Related]
10. Synergetic effect of Azacitidine and Sorafenib in treatment of a case of myeloid neoplasm with sole chromosomal abnormality t(8;22)(p11.2;q11.2)/BCR-FGFR1 rearrangement.
Dhangar S; Shanmukhaiah C; Sawant L; Ghatanatti J; Shah A; Mathan S LP; Vundinti BR
Cancer Genet; 2023 Jun; 274-275():26-29. PubMed ID: 36965231
[TBL] [Abstract][Full Text] [Related]
11. Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of
Baer C; Muehlbacher V; Kern W; Haferlach C; Haferlach T
Haematologica; 2018 Aug; 103(8):e348-e350. PubMed ID: 29567772
[No Abstract] [Full Text] [Related]
12. Acute leukemia with cytogenetically cryptic FGFR1 rearrangement and lineage switch during therapy: A case report and literature review.
McKeague SJ; O'Rourke K; Fanning S; Joy C; Throp D; Adams R; Harvey Y; Keng TB
Am J Clin Pathol; 2024 Feb; 161(2):197-205. PubMed ID: 37855739
[TBL] [Abstract][Full Text] [Related]
13. A ZMYM2-FGFR1 8p11 myeloproliferative neoplasm with a novel nonsense RUNX1 mutation and tumor lysis upon imatinib treatment.
Buijs A; van Wijnen M; van den Blink D; van Gijn M; Klein SK
Cancer Genet; 2013 Apr; 206(4):140-4. PubMed ID: 23751892
[TBL] [Abstract][Full Text] [Related]
14. Activity of Pemigatinib in Pilocytic Astrocytoma and
Capone S; Ketonen L; Weathers SP; Subbiah V
JCO Precis Oncol; 2022 Apr; 6():e2100371. PubMed ID: 35507888
[No Abstract] [Full Text] [Related]
15. Proteomic analysis reveals dual requirement for Grb2 and PLCγ1 interactions for BCR-FGFR1-Driven 8p11 cell proliferation.
Peiris MN; Meyer AN; Warda D; Campos AR; Donoghue DJ
Oncotarget; 2022; 13():659-676. PubMed ID: 35574218
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetic Evolution Associated With Disease Progression in Hematopoietic Neoplasms With t(8;22)(p11;q11)/BCR-FGFR1 Rearrangement.
Wang W; Tang G; Kadia T; Lu X; Li Y; Huang L; Montenegro-Garreaud X; Miranda RN; Wang SA
J Natl Compr Canc Netw; 2016 Jun; 14(6):708-11. PubMed ID: 27283163
[TBL] [Abstract][Full Text] [Related]
17. Clinicogenomic Analysis of
Silverman IM; Hollebecque A; Friboulet L; Owens S; Newton RC; Zhen H; Féliz L; Zecchetto C; Melisi D; Burn TC
Cancer Discov; 2021 Feb; 11(2):326-339. PubMed ID: 33218975
[TBL] [Abstract][Full Text] [Related]
18. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.
Liu PCC; Koblish H; Wu L; Bowman K; Diamond S; DiMatteo D; Zhang Y; Hansbury M; Rupar M; Wen X; Collier P; Feldman P; Klabe R; Burke KA; Soloviev M; Gardiner C; He X; Volgina A; Covington M; Ruggeri B; Wynn R; Burn TC; Scherle P; Yeleswaram S; Yao W; Huber R; Hollis G
PLoS One; 2020; 15(4):e0231877. PubMed ID: 32315352
[TBL] [Abstract][Full Text] [Related]
19. Myeloid and lymphoid neoplasms with FGFR1 abnormalities: diagnostic and therapeutic challenges.
Savage NM; Johnson RC; Gotlib J; George TI
Am J Hematol; 2013 May; 88(5):427-30. PubMed ID: 22886804
[No Abstract] [Full Text] [Related]
20. [New European approvals: Pemigatinib - cholangiocarcinoma with a FGFR2 fusion or rearrangement].
Delaye M; Pernot S
Bull Cancer; 2021 May; 108(5):446-447. PubMed ID: 33931169
[No Abstract] [Full Text] [Related]
[Next] [New Search]
